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Macrophages regulate many developmental and pathological processes in both embryonic and adult tissues, and
recent studies have shown a significant role in angiogenesis. Similarly, Wnt signaling is fundamental to tissue
morphogenesis and also has a role in vascular development. In this review, we summarize recent advances in the
field of macrophage-regulated angiogenesis, with a focus on the role of macrophage-derived Wnt ligands. We
review data that provide both direct and indirect evidence for macrophage-derived Wnt regulation of physiologic
and pathologic angiogenesis. Finally, we propose that Wnt signaling plays a central role in differentiation of tumor
associated and wound infiltrating macrophages to a proangiogenic phenotype.
Keywords: Macrophage, Angiogenesis, WntIntroduction
Angiogenesis is the growth of new blood vessels from the
existing vasculature. This process plays critical roles in
both development and pathological conditions such as
tumor growth and diabetic retinopathy [1]. During angio-
genesis, endothelial cells (EC) coordinate signals derived
from a multitude of stromal cells in close proximity to the
blood vessels, including fibroblasts, smooth muscle cells/
pericytes and macrophages [2]. Growth factors, proteases
and extracellular matrix (ECM) components derived from
these stromal cells participate in the process [1]. In this re-
view, we will focus on the role of macrophage-derived
Wnt signals in regulating angiogenesis.
Members of the Wnt protein family have been shown to
regulate diverse biological processes including cell prolif-
eration, apoptosis, polarity, differentiation and the main-
tenance of pluripotency in stem cells [3]. Wnt proteins
have been studied extensively, but only recently has their
function in angiogenesis begun to be elucidated. Macro-
phages comprise a diverse group of cells from the mono-
nuclear phagocytic lineage [4]. They are highly plastic,
exhibiting dramatic changes in phenotype in response to
various stimuli and, in addition, are believed to exist in a* Correspondence: cchughes@uci.edu
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distribution, and reproduction in any mediummultitude of subpopulations [4-6]. This review is not
intended to be an overview of different macrophage phe-
notypes and subpopulations, instead, we highlight studies
showing an angiogenic function for a variety of the differ-
ent subpopulations of macrophages. We will employ a
general definition of macrophages as any non-dendritic
cell of monoblast origin, which includes monocytes and
the specialized tissue-resident macrophages of the central
nervous system, microglial cells. Increasing evidence sug-
gests that macrophages mediate their effects on angiogen-
esis, in part, through secretion of members of the Wnt
family of secreted glycoproteins.The role of Wnts in angiogenesis
In humans, Wnt signaling is mediated by a family of 19
secreted Wnt glycoproteins and 10 transmembrane
Frizzled (Fzd) receptors [7]. Although the distinction is
becoming less clear [8,9] Wnt signaling is generally
broken down into the canonical, Wnt/β-catenin path-
way, and the non-canonical, Wnt/Calcium and planar
cell polarity (PCP) pathway. In the canonical Wnt path-
way, Wnt ligand binding to Fzd and the co-receptors,
LDL-receptor-related proteins-5 or −6 (Lrp5/6), leads to
cytosolic β-catenin accumulation. β-catenin then trans-
locates to the nucleus where it binds to transcription
factors of the lymphocyte enhancing factor (LEF)/T-cell
factor (TCF) family, thereby activating transcription of a
number of target genes [7,10]. Non-canonical Wntsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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receptor tyrosine kinase-like orphan receptor (Ror) fam-
ily and the Wnt modifier, receptor-like tyrosine kinase
(Ryk). This pathway leads to changes in cell polarity and
migration and is mediated by Ca2+influx as well as acti-
vation of the small GTPases, RhoA, Cdc42 and Rac
[11,12]. A detailed overview of Wnt signaling is beyond
the scope of this review and the reader is referred to
many excellent reviews [7,8,10,11] as well as the Wnt
Gene Homepage at http://www.stanford.edu/~rnusse/
wntwindow.html.
Evidence for Wnt signals regulating angiogenesis is
provided firstly by reports of ECs expressing a number
of Wnt receptors including Fzd1, Fzd2, Fzd4, Fzd5,
Fzd6, Fzd7, Fzd9, Fzd10, Lrp5, Lrp6 and the Wnt signal-
ing modulator,Ryk [13-16]. It is not surprising then, that
there are numerous reports showing that EC respond to
Wnt proteins in vitro. Wnt1, Wnt3a and Wnt5a have all
been shown to control EC proliferation and in some
cases migration [17-23], two processes critical for angio-
genesis. In addition, the Wnt antagonist, secreted
frizzled-related protein 1 (sFRP1) reduces EC prolifera-
tion [24] and canonical Wnt signaling was shown to pro-
mote tube-like formation on Matrigel [25]. Masckauchan
et al. have shown that Wnt5a induces expression of Tie-2
in human umbilical vein endothelial cells (HUVEC), a re-
ceptor tyrosine kinase involved in EC survival and matur-
ation [19] and we have independently confirmed this
finding in our lab (unpublished observations). Thus, it is
clear that Wnt signaling pathways can regulate angiogen-
esis in vitro.
The story is much the same in vivo, with several
reports of active Wnt signaling in EC undergoing angio-
genesis [26-33]. Moreover, many Wnt signaling pathway
alterations lead to vascular defects. β-catenin nuclear
localization has been observed in capillaries during
human development [28] and various reporter mice have
shown that canonical Wnt signaling is active in EC dur-
ing developmental angiogenesis [27,30,31]. β-catenin has
also been shown to accumulate in the nucleus of EC
undergoing pathological angiogenesis in rat models of
myocardial infarction [26] and glioma [32] as well as in
human tumors of the central nervous system [29,33]. Of
note, β-catenin nuclear localization is rarely seen in
adult quiescent EC [26,29,32,33]. Changes in Wnt signal-
ing pathways have also been correlated with angiogen-
esis. For example, endothelial-specific β-catenin gain-of-
function mutant mice are embryonic lethal and display
decreased vessel lengths and increased lumen diameter
[34]. These mice also display upregulated Notch signal-
ing, another important mediator of vessel growth [34].
Injection of cells overexpressing Wnt1 and Wnt3a into
the chick paraxial mesoderm leads to increased vascular
density [35], and disruption of the Wnt2 gene in miceresults in placental vascular defects with a decrease in
the number of fetal capillaries [36].
Disturbing Wnt receptor expression in vivo can also lead
to vascular defects, with the most well-studied receptors
being Fzd4 and Fzd5. Fzd4 loss-of-function mutations have
been linked to familial exudative vitreoretinopathy (FEVR),
a disease characterized by abnormal retinal vasculature
[37]. Furthermore, Fzd4 deletion in mice has been shown
to alter vessel formation in the cerebellum and the retina
[38]. However, at least in the retina, one Fzd4 ligand is
Norrin, which is not a Wnt family member, but does acti-
vate the canonical Wnt signaling pathway [38]. In a recent
study, Descamps et al. showed that Fzd4−/− mice display
significant reductions in arteriole density in the heart and
kidney as well as impaired angiogenesis in a mouse model
of hind limb ischemia [39]. The evidence presented in that
study suggests that the Fzd4 ligand is a non-canonical
Wnt. Fzd5 knockout (KO) mice are embryonic lethal due
to defects in yolk sac angiogenesis. Specifically, EC prolif-
eration is impaired and an incomplete capillary plexus is
formed [40]. A more recent study using a conditional gen-
etic deletion of Fzd5 to bypass the perinatal lethality
observed in the original KO mouse, shows that this Wnt
receptor also regulates blood vessel development [41].
Clearly there is a plethora of evidence implicating Wnt
signaling in modulating angiogenesis. For a more exten-
sive overview of the literature, the reader is referred to
several recent reviews [42-44].
Macrophages in angiogenesis
There is substantial evidence that macrophages play a sig-
nificant role in both physiological and pathological angio-
genesis [4,45,46]. In mouse development the first
macrophages appear at 7.5 days post-coitum (dpc) and
starting between 8 and 9.5 dpc they can be found in both
extra-embryonic and embryonic tissue [47], placing them
in prime position to regulate angiogenesis. In support of
this idea, embryonic macrophages, compared to circulat-
ing adult macrophages, have been shown to have “wound
healing” and “angiogenesis” gene expression signatures
[48]. Macrophages colonize the mouse embryonic hind-
brain independently of blood vessel formation and Fantin
et al. showed that these tissue-resident macrophages asso-
ciated with angiogenic tip cells during the same time
period that neighboring vessels were anastomosing with
one another [49]. Ablation of macrophages, using both
PU.1−/− and Csf-1op/op mice, resulted in a decreased num-
ber of vessel intersections in the hindbrain, providing the
first evidence that macrophages actively participate in ves-
sel anastomosis [49]. Interestingly, these tissue-resident
macrophages were shown to express Tie-2 and NRP1, two
genes that are known to be significantly upregulated in
proangiogenic macrophages [47]. Also of note, the effect
of these macrophages on angiogenesis is not mediated by
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[49]. However, the study does not rule out the possibility
that macrophages secrete other VEGF isoforms that con-
tribute to angiogenesis. Evidence for macrophages regulat-
ing vessel anastomosis in other tissues comes from studies
in the mouse retina [49-51]. Outtz and colleagues pro-
vided evidence that macrophage Notch1 regulates this
process [50] and studies from Rymo et al. indicate that
microglial-secreted factors other than VEGF-A increase
vessel sprouting and branching in the rat aortic ring
model of angiogenesis [51].
Macrophages, given their ability to migrate within virtu-
ally all tissues of the body, are also an ideal cell to regulate
angiogenesis during tissue injury and repair. Using, a
transgenic mouse model of ischemic cardiomyopathy,
Moldovan et al. showed that macrophages carved out tun-
nels in the ECM, thereby providing avenues for subse-
quent capillary infiltration [52]. Macrophages are actively
recruited to wound sites and macrophage-depletion dur-
ing early phases of the wound healing process leads to
reduced formation of vascularized granulation tissue,
whereas depletion during later phases caused severe
hemorrhage and prevented wound closure [53]. These
findings implicate macrophages in mediating both the ini-
tial and maturation stages of angiogenesis. A separate
study showed that wound healing was delayed in
macrophage-deficient Csf-1op/op mice and this correlated
with decreased vascular density [54]. Thus, although it is
well known that macrophages serve an immune function
during tissue repair, it is also clear that they play a trophic
role through the regulation of angiogenesis.
A rapidly developing field is the study of tumor-
associated macrophages (TAMs) and their role in pro-
moting tumor progression. It comes as no surprise that
TAMs mediate some of their effects on tumor growth by
regulating angiogenesis [45,46,55,56]. TAMs can be
recruited to tumors by a number of different cytokines,
including CCL2 and CSF-1/M-CSF [57-59]. TAMs have
been shown to regulate tumor angiogenesis in a number
of different tissues including bone, brain, breast, cervix,
colon and lung, among others [60-66]. They have been
shown to mediate angiogenesis in part by secretion of
VEGF, along with proteases, such as matrix metallopro-
teinases (MMPs) [64,67]. Interestingly, studies by De
Palma and colleagues have shown that the majority of
proangiogenic TAMs in tumors are Tie-2 expressing
monocytes (TEMs) [47,68], implicating Tie-2 as an im-
portant marker of proangiogenic macrophages. Indeed,
Angiopoietin-2 (Ang-2) signaling via Tie-2 in TEMs has
been shown to upregulate proangiogenic genes [69]. Al-
though TEMs have been shown to exist as a subset of
circulating monocytes [68], studies have shown that con-
ditions of hypoxia can upregulate Tie-2 expression in
monocytes [70]. As in EC [19], Tie-2 expression inmacrophages may also be regulated by Wnt5a. It is clear
that macrophages regulate angiogenesis through mul-
tiple mechanisms, however, a detailed discussion on the
role of macrophage-derived cytokines in angiogenesis is
beyond the scope of this review.
Macrophage-derived Wnts regulate angiogenesis
Based on the studies outlined above, it is evident that both
macrophages and secreted Wnt proteins regulate angio-
genesis. It may, therefore, be reasonable to hypothesize
that Wnt ligands mediate some of the effects that macro-
phages have on angiogenesis, and indeed, macrophages do
express Wnt ligands. Interferon-γ (IFN-γ) and lipopoly-
saccharide (LPS), two potent inducers of inflammation,
lead to significant upregulation of Wnt5a transcript and
protein levels in macrophages [71]. Furthermore, Wnt5a
can signal in an autocrine manner to induce expression of
several pro-inflammatory cytokines in macrophages in-
cluding IL-6, IL-8 and IL-1β [71], all of which have been
shown to be pro-angiogenic [72-75]. Given that Wnt5a
has also been shown to induce expression of several in-
flammatory cytokines in EC, including IL-6 and IL-8 [76]
combined with the direct effects that Wnt5a has on EC
proliferation, migration and Tie-2 expression [18,19,22], it
is reasonable to hypothesize that macrophage-derived
Wnt5a regulates angiogenesis via both direct and indirect
mechanisms and at multiple levels. Moreover, as Wnt5a
has also been shown to upregulate expression of the
macrophage chemotactic protein, CCL2, in EC [76], it is
possible that macrophage-derived Wnt5a could indirectly
drive additional rounds of macrophage recruitment.
Aside from inflammatory angiogenesis, research in
cancer biology also points to a role for macrophage-
derived Wnts in regulating tumor angiogenesis. Smith
et al. looked at Wnt expression in 14 matched cases of
normal, adenomatous and malignant colorectal tissues
and reported upregulation of Wnt gene expression in
TAMs, in particular, Wnt2 and Wnt5a, during the pro-
gression from normal through adenoma to carcinoma in
colorectal tissue [77]. Of note, the angiogenic switch in
colorectal cancer is thought to occur during the progres-
sion from adenoma to carcinoma [78]. As mentioned
earlier, TAMs play an essential role in breast cancer
angiogenesis [60,61]. Ojalvo et al. separated “invasive”
TAMs from general TAMs using an in vivo migration
assay [79] combined with fluorescent activated cell sort-
ing (FACS) [80], and used gene expression analysis to
show that “invasive” TAMs were enriched for Wnt sig-
naling molecules [80]. Based on these findings and
others, Qian and Pollard recently hypothesized that this
subset of Wnt-expressing-TAMs may link angiogenesis
and tumor invasion [46]. Further investigation is needed
to confirm the role of macrophage-derived Wnts in































































Figure 1 Model for macrophage-derived Wnt5a regulation of angiogenesis. (A) A wound or inflammation induces secretion of cytokines,
including the macrophage chemotactic cytokines M-CSF and CCL2, by fibroblasts, pericytes, EC and other stromal cells present at the site of
injury. (B) Monocytes extravasate from the blood vessels and secrete Wnt5a, which upregulates expression of Tie2 in macrophages and EC (note:
basal levels of Tie-2 expression not depicted) as well as induces proliferation and migration of sprouting EC. (C) EC and pericyte-derived Ang2
signals through Tie2 expressed on the surface of TEMs, further polarizing macrophages to a proangiogenic phenotype. (D) TEMs then participate
in the maturation phases of angiogenesis, including vessel lumen formation and anastomosis.
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derived Wnts in regulating hyaloid vascular remodeling
and developmental angiogenesis in the retina comes from
studies by Lang and colleagues. The hyaloid vessel system
is laid down during development of the eye and requires
remodeling after birth to allow for unobstructed vision
[81]. Macrophages are in close contact with these vessels
and genetic approaches that deplete macrophages lead to a
loss of remodeling and the persistence of these vessels
post-natally [82]. Further examination revealed that macro-
phage secretion of the canonical Wnt protein, Wnt7b, is
required for this process [83]. Specifically, pericyte secre-
tion of Ang-2 induces Wnt7b expression in macrophages;
Wnt7b then stimulates vascular EC entry into the S phase
of the cell cycle. Pericyte secretion of Ang-2 inhibits
Ang-1-mediated survival signaling in EC and also signals
through β-catenin to induce cell cycle entry and subse-
quent apoptosis [83,84]. The authors hypothesize that the
need for macrophage-derived Wnt7b allows for coordin-
ation of apoptosis and phagocytosis [84].
Non-canonical Wnts secreted by macrophages also
regulate vessel branching in the mouse retina. Shortlyafter birth, vessels from the superficial vascular plexus on
the surface of the retina sprout vertically, down through
the ganglion. Upon reaching the outer edge of the inner
nuclear layer, EC turn and branch to form the deep vascu-
lar plexus [85]. Stefater et al. showed that retinal myeloid
cells (RMC) are in close contact with tip cells of EC
sprouts at the point of branching and remained associated
after EC extend within the plane of the deep retinal layer
[86]. They further showed that this population of RMCs is
different than RMCs found in the superficial vascular
layer. Specifically, they express the non-canonical Wnt
ligands, Wnt5a and Wnt11, whereas superficial RMCs do
not [86]. The authors also demonstrated that myeloid-
specific deletion of the gene for the Wnt ligand trans-
porter Wls, a protein required for Wnt secretion [87],
resulted in increased vascular density of the deep vascular
plexus, a phenotype shared by Wnt5a+/− and Wnt11+/−
heterozygotes. The mechanism was shown to involve
an autocrine-signaling axis where macrophage-derived
Wnt5a and Wnt11 induce secretion of the soluble VEGF
inhibitor Flt1 [88,89] that, in turn, inhibits vessel branch-
ing [86].
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regulation by macrophages and we anticipate that future
research in this field will reveal an even more crucial role
for these proteins in this process.
Conclusions and perspective
We have laid out evidence indicating that macrophages
regulate angiogenesis, in part, through secreting and
responding to Wnt signaling glycoproteins. This is true in
both developmental and pathological angiogenesis. It is
interesting and perhaps not unexpected that in some cases
Wnts seem to be pro-angiogenic, as is the case for Wnt5a-
induced EC proliferation and migration [19,20], and in
other cases inhibitory, for example Wnt5a inhibition of
vessel branching in the retinal deep vascular plexus [86].
One possible explanation for this relates to the fact that
angiogenesis is a series of events with different morpho-
logical changes required at different stages. Therefore, the
same protein may inhibit or induce angiogenesis depend-
ing on the stage of angiogenesis at which it is present. We
also reason that these differences are due to differential
Wnt receptor expression on the various cells responding
to the signal as well as different signaling proteins that are
present in the microenvironment. Coordinated crosstalk of
Wnt signaling pathways with other pathways in EC such as
Notch/Dll4, VEGF, Ang1/2 and focal adhesion kinase
(FAK) [90] ultimately will determine the nature of the re-
sponse. Furthermore, the cell population in a given tissue
will likely alter the angiogenic response to macrophage-
derived Wnts. We have discussed Wnt signaling in ECs
and macrophages, but it is likely that Wnt binding to fibro-
blasts, smooth muscle cells and pericytes alters their
phenotype as well. In the cases described above, differences
in the effect of Wnt5a on angiogenesis could be explained
by which cells bind the Wnt5a ligand. Wnt5a binding dir-
ectly on the EC induces proliferation and migration,
whereas Wnt5a signaling in an autocrine manner in
macrophages leads to upregulation of the soluble VEGF in-
hibitor, Flt1, to reduce vessel branching.
Based on the studies that we have presented in this re-
view, we hypothesize that Wnt5a is a crucial mediator of
macrophage phenotype. It is known that Wnt5a induces
Tie-2 expression in EC [19] and it would be interesting to
determine if macrophages respond in the same manner, es-
pecially as TEMs are known to be critical mediators of
angiogenesis [47,68,69]. This would implicate Wnt5a as an
important determinant of macrophage differentiation from
an inflammatory function to a more trophic function. We
propose a model where wounding or inflammation leads to
a release of inflammatory cytokines, including the macro-
phage chemotactic proteins CCL2 and M-CSF (Figure 1A).
Upon recruitment, macrophages release Wnt5a, which
induces EC proliferation and migration, but also upregu-
lates Tie-2 expression in macrophages and EC (Figure 1B).These Tie-2 expressing macrophages (TEM) respond to
Ang-2 secreted by EC and pericytes and polarize into a
more proangiogenic macrophage [69] (Figure 1C). During
later stages of angiogenesis these TEMs aid in vessel anas-
tomosis and maturation (Figure 1D).
Additionally, studies of TAMs show that “invasive”
TAMs in breast cancer are enriched for Wnt signaling
pathway components [80] and colon cancer progression
correlates with increased Wnt5a expression in TAMs [77].
These observations, combined with studies implicating
TEMs as the predominant proangiogenic macrophage
within the tumor microenvironment [47,68], suggest that
this model may be relevant to tumor angiogenesis as well,
especially in light of the tumor being a “wound that does
not heal” [91]. Owing to the perinatal lethality exhibited
by Wnt5a-null mice [92], it has been difficult to study its
function in vivo. Until conditional Wnt5a KO mice are
made, we anticipate that complex three-dimensional
in vitro models that incorporate macrophages and allow
for easy manipulation of cells will be vital in elucidating
the role that this signaling pathway plays in macrophage-
regulation of angiogenesis. Looking ahead, we foresee
more sophisticated experimental systems uncovering an
even greater role for macrophage-derived Wnt ligands in
regulating angiogenesis.
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